Table 7.
Contrast tests of mean score differences on symptom severity, quality of life, and four patterns of body constitution at three post-tests (n = 240)
|
RQLQ-S for SS |
RQLQ-S for QOL |
Gentleness |
Qi-deficiency |
Yang-deficiency |
Inherited special |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Slope |
MD |
Slope |
MD |
Slope |
MD |
Slope |
MD |
Slope |
MD |
Slope |
MD |
|
| (SE) | ( P ) | (SE) | ( P ) | (SE) | ( P ) | (SE) | ( P ) | (SE) | ( P ) | (SE) | ( P ) | |
|
T2 |
|
|||||||||||
| CS vs. placebo |
23.12 (7.59) |
-26.13 (0.001) |
11.67 (3.96) |
-12.81 (0.001) |
-3.29 (1.99) |
6.18 (0.002) |
5.88 (2.56) |
-7.87 (0.002) |
4.45 (3.08) |
-8.53 (0.006) |
6.43 (2.45) |
-5.22 (0.03) |
| CS vs. YS |
6.61 (7.57) |
-5.28 (0.49) |
5.05 (3.95) |
-4.23 (0.28) |
-1.32 (1.99) |
3.16 (0.11) |
5.74 (2.56) |
-2.46 (0.34) |
3.97 (3.08) |
-5.08 (0.10) |
3.24 (2.44) |
-1.94 (0.43) |
| YS vs. placebo |
2.33 (7.61) |
-20.85 (0.006) |
2.05 (3.97) |
-8.58 (0.03) |
-1.97 (2.01) |
3.01 (0.13) |
0.14(2.58) |
-5.41 (0.04) |
0.48 (3.09) |
-3.45 (0.27) |
3.19 (2.46) |
-3.27 (0.18) |
|
T3 |
|
|||||||||||
| CS vs. placebo |
29.64 (7.59) |
-32.64 (<0.0005) |
15.61 (3.96) |
-16.76 (<0.0005) |
-3.03 (1.99) |
5.93 (0.003) |
4.49 (2.57) |
-6.47 (0.01) |
2.35 (3.09) |
-6.42 (0.04) |
3.79 (2.45) |
-2.58 (0.29) |
| CS vs. YS |
12.12 (7.57) |
-10.79 (0.15) |
6.12 (3.95) |
-5.31 (0.18) |
-1.00 (1.99) |
2.84 (0.15) |
6.14 (2.56) |
-2.85 (0.26) |
4.29 (3.09) |
-5.40 (0.08) |
2.09 (2.44) |
-0.80 (0.74) |
| YS vs. placebo |
2.12 (7.61) |
-21.85 (0.004) |
2.75 (3.98) |
-11.46 (0.004) |
-2.03 (2.00) |
3.09 (0.12) |
-1.65 (2.58) |
-3.62 (0.16) |
-1.94 (3.10) |
-1.03 (0.74) |
1.70 (2.46) |
-1.78 (0.47) |
|
T4 |
|
|||||||||||
| CS vs. placebo |
31.54 (7.59) |
-34.54 (<0.0005) |
14.71 (3.96) |
-15.86 (<0.0005) |
0.95 (1.99) |
1.95 (0.33) |
3.71 (2.56) |
-5.70 (0.03) |
2.83 (3.05) |
-6.90 (0.02) |
8.35 (2.44) |
-7.14 (0.003) |
| CS vs. YS |
8.80 (7.57) |
-7.47 (0.32) |
4.93 (3.94) |
-4.11 (0.30) |
0.57 (1.99) |
1.27 (0.52) |
4.54 (2.56) |
-1.27 (0.62) |
3.92 (3.04) |
-5.03 (0.10) |
4.03 (2.44) |
-2.73 (0.26) |
| YS vs. placebo | 2.93 (7.61) | -27.07 (<0.0005) | 2.97 (3.97) | -11.74 (0.003) | 0.38 (2.00) | 0.67 (0.74) | -0.83 (2.57) | -4.44 (0.08) | -1.09 (3.06) | -1.87 (0.54) | 4.32 (2.45) | -4.40 (0.07) |
RQLQ-S, Rhinoconjunctivitis Quality of Life Questionnaire Standard; SS, Symptom severity; QOL, Quality of life; CS, Cure-allergic-rhinitis Syrup group; YS, Yu-ping-feng San group MD, Mean difference between two groups; SE, Standard error in Generalised Estimating Equation (GEE) test.
T1, baseline at subject recruitment; T2, immediately after intervention; T3, one month after intervention; T4, three months after intervention.